Phenylalanine

Generic Name: Phenylalanine

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₁NO_₂

CAS Number: 63-91-2

Unique Ingredient Identifier: 47E5O17Y3R

Background: Phenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.

Indication: L-phenylalanine may be helpful in some with depression. It may also be useful in the treatment of vitiligo. There is some evidence that L-phenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs.

Associated Therapies: Amino acid supplementation

Clinical Trials

Improving Multivitamin Supplementation to Pregnant Women

Phase 4

Completed

Conditions: Nausea
Pregnancy
Vomiting
Hyperemesis Gravidarum
Morning Sickness

Interventions: Drug: Pregvit®
Drug: Orifer F®

First Posted Date: 2014-11-24

Last Posted Date: 2014-11-24

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 1370

Registration Number: NCT02300155

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

Phase 1

Recruiting

Conditions: Congenital Hyperinsulinism
Insulinoma

Interventions: Drug: Fluorodopa F 18

First Posted Date: 2013-12-27

Last Posted Date: 2024-07-16

Lead Sponsor: Cook Children's Health Care System

Target Recruit Count: 250

Registration Number: NCT02021604

Locations: 🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Treatment A
Drug: Treatment D
Drug: Treatment B
Drug: Treatment C
Drug: Treatment E
Drug: Treatment F
Drug: Treatment G
Drug: Treatment H
Drug: Treatment I
Drug: Treatment J

First Posted Date: 2013-04-26

Last Posted Date: 2014-02-07

Lead Sponsor: Gilead Sciences

Target Recruit Count: 56

Registration Number: NCT01841489

Locations: 🇺🇸
Investigational Site, Daytona Beach, Florida, United States

A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris

Phase 1

Completed

Conditions: Psoriasis Vulgaris

First Posted Date: 2012-04-19

Last Posted Date: 2025-03-12

Lead Sponsor: LEO Pharma

Target Recruit Count: 24

Registration Number: NCT01580488

Locations: 🇫🇷
Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD) - Hôpital l'Archet 2, 151 route Saint-Antoine de Ginestière, Nice, France

This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment F
Drug: Treatment C
Drug: Treatment D
Drug: Treatment A
Drug: Treatment B
Drug: Treatment G
Drug: Treatment E

First Posted Date: 2011-01-07

Last Posted Date: 2018-12-03

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT01272375

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Treatment D
Drug: Treatment A
Drug: Treatment B
Drug: Treatment E
Drug: Treatment F
Drug: Treatment C

First Posted Date: 2010-11-19

Last Posted Date: 2019-02-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 31

Registration Number: NCT01244035

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D
Drug: Treatment E
Drug: Treatment F
Drug: Treatment G

First Posted Date: 2010-08-13

Last Posted Date: 2011-01-24

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT01181700

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment

Phase 2

Conditions: Osteoarthritis

Interventions: Drug: kondrium f
Drug: kondrium
Drug: methyl prednisolone (corticosteroid)

First Posted Date: 2009-09-15

Last Posted Date: 2010-01-20

Lead Sponsor: Nucitec

Target Recruit Count: 114

Registration Number: NCT00977444

Locations: 🇲🇽
Hospital San Jose, Queretaro, Mexico

A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment D
Drug: Treatment A
Drug: Treatment B
Drug: Treatment E
Drug: Treatment F
Drug: Treatment C

First Posted Date: 2009-07-27

Last Posted Date: 2013-03-19

Lead Sponsor: Tibotec BVBA

Target Recruit Count: 28

Registration Number: NCT00946842

Effects of Aquamin F on NSAID Dose Reduction in Osteoarthritis of the Knee

Phase 1

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Drug: Placebo (maltodextran)
Drug: Aquamin F

First Posted Date: 2008-09-19

Last Posted Date: 2008-09-19

Lead Sponsor: Marigot Ltd.

Target Recruit Count: 29

Registration Number: NCT00755482

Locations: 🇺🇸
Minnesota Applied Research Center, Edina, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy